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Abstract
Purpose We sought to compare the quality of life (QOL),
characteristics, and survival of patients with non-Hodgkin
lymphoma (NHL) with and without human immunodeﬁ-
ciency virus (HIV) infection.
Methods Using the population-based cancer registry for
Orange and San Diego Counties, We recruited 50 patients
with HIV and systemic NHL (cases) and 50 age, sex and
race-matched NHL patients without HIV (controls) diag-
nosed with NHL during 2002–2006. Patients completed a
medical history survey and QOL instrument, the Functional
Assessment of Human Immunodeﬁciency Virus Infection
(FAHI) for cases and Functional Assessment of Cancer
Therapy-General (FACT G) for controls.
Results HIV-infected patients had worse overall QOL
and survival than uninfected patients. QOL differences
were more marked in the areas of functional, physical and
social well-being than in the area of emotional well-being.
HIV-infected patients had lower income and were less
likely to have private insurance and more likely to have
diffuse large B cell histology than uninfected patients.
Conclusion HIV-infected NHL patients had worse QOL
and survival than uninfected patients, due to a combination
of co-morbidity, aggressive histology and lack of social
support. However, their emotional well-being was com-
parable to that of uninfected NHL patients and better than
historical norms for the HIV-infected.
Keywords HIV   AIDS   Quality of life  
Non-Hodgkin lymphoma   FAHI   FACT G
Abbreviations
AIDS Acquired immunodeﬁciency syndrome
DLBCL Diffuse large B cell lymphoma
FACT G Functional assessment of cancer therapy-
general
FAHI Functional assessment of human
immunodeﬁciency virus infection
GLM General linear model
G-CSF Granulocyte colony-stimulating factor
HAART Highly active antiretroviral therapy
HIV Human immunodeﬁciency virus
ICD-O International classiﬁcation of diseases for
oncology
MANOVA Multivariate analysis of variance
NHL Non-Hodgkin lymphoma
QOL Quality of life
SD Standard deviation
Introduction
Non-Hodgkin lymphoma (NHL) has been a major source
of morbidity and mortality among individuals with human
immunodeﬁciency virus (HIV) since the ﬁrst description of
acquired immunodeﬁciency syndrome (AIDS) in the early
1980s [1]. Regarding lymphoma patients without HIV, an
increased focus on quality of life (QOL) has emerged [2].
However, there are few studies of HIV-associated NHL
that focus on QOL. We are aware of a single paper
reporting QOL among HIV-infected patients who received
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DOI 10.1007/s11136-009-9565-0oral combination chemotherapy with ﬁlgrastim (granulo-
cyte colony-stimulating factor (G-CSF) [3]. Indeed, a
recent Cochrane review of treatment of AIDS-related NHL
speciﬁcally requested more trials with QOL as an endpoint
[4]. Addressing this knowledge gap, we performed a case–
control study comparing QOL as well as clinical charac-
teristics between patients with HIV and NHL and NHL
without HIV infection.
Since the introduction of highly active antiretroviral
therapy (HAART) in the late 1990s, survival among
patients with AIDS-related NHL has improved dramati-
cally [5]. While physicians 10 years ago were hesitant to
treat patients with AIDS and NHL with chemotherapy,
contemporary patients typically receive the same aggres-
sive chemotherapy regimens that patients without AIDS
receive [6]. Despite these therapeutic improvements, we
hypothesized that contemporary patients with HIV infec-
tion and NHL would have worse QOL than contemporary
uninfected patients with NHL and historical HIV-infected
patients.
HIV-infected NHL patients differ from NHL patients
without HIV infection. They are typically younger and
more likely to be male and racial/ethnic minorities [7].
Because of these demographic differences, we matched by
age, race and sex in comparing NHL patients with and
without HIV-infection. Also, HIV-infected individuals
(with or without concurrent NHL) are more likely to be
poor, publicly insured, and illicit drug users than unin-
fected individuals [8]. Because of the social stigma asso-
ciated with HIV and its associated sexual and drug-related
risk factors, the HIV-infected may feel rejected by their
families and society as a whole. Compared with uninfected
NHL patients, those with concurrent HIV and NHL have an
additional co-morbidity which requires medication and
may have caused pre-existing disability. NHL histology
among the HIV-infected typically is more aggressive than
among patients without HIV [1]. Because of these social
and biologic differences between NHL patients with and
without HIV infection, we anticipated that we would ﬁnd a
lower QOL among the HIV-infected NHL patients in all
categories of well-being measured: emotional, social,
physical and functional.
Methods
The University of California Irvine Institutional Review
Board approved the study prior to initiation (#2002-2428)
in accordance with the 1964 Declaration of Helsinki. We
recruited 100 residents of Orange or San Diego Counties
diagnosed with systemic NHL from 2002–2006, 50 HIV-
infected and 50 without HIV diagnoses. We identiﬁed
subjects through the California cancer registry for Orange
and San Diego Counties and provider referrals. We sought
to contact patients within 1 year of their NHL diagnosis.
Prior to contacting a patient, we sent a letter to the
reporting physician to determine if there was any reason to
not contact the patient. If there were no contraindications,
we sent a packet with the consent form, medical record
release form, medical history survey and QOL instrument
to the potential subject along with a cover letter explaining
the study. If the potential subject did not return the signed
consent and surveys, a research associate telephoned the
subject to answer questions, encourage participation and
offer assistance completing the packet.
During 2002–2006, the California Cancer Registry for
Orange and San Diego Counties contained 171 patients
ﬂagged as HIV-infected (potential cases) and 4,932
patients with systemic NHL ﬂagged as HIV-seronegative
or sero-unknown (potential controls). In previous research
we have demonstrated this HIV ﬂag to be 97% sensitive
and 92% speciﬁc [9]. Of the 171 potential cases, we
recruited 51. Thirty potential cases died prior to contact
and we were unable to make contact with 15; one was too
ill to participate. The remaining 74 potential cases were
reported to the Cancer Registry too late to be eligible for
the study (more than 1 year after NHL diagnosis). We
excluded one case from analysis because we did not have a
control for him. We attempted to contact 130 controls with
an initial goal of a 2:1 case:control ratio. Seven potential
controls died prior to contact; we were unable to make
contact with 37 and 16 declined participation. Although we
recruited 70 controls, we selected the 50 sex and race-
matched controls with complete data that matched the
cases by age (±5 years) in order to achieve a 1:1
case:control ratio. Thus, the analysis included 50 cases and
50 controls.
The QOL instrument was the Functional Assessment of
Human Immunodeﬁciency Virus Infection (FAHI) in
patients with HIV and the Functional Assessment of Can-
cer Therapy-General (FACT G) in patients without HIV
[10, 11]. These QOL instruments have been validated in
English and Spanish [12, 13] and all patient forms and
surveys were available in both languages. The FAHI con-
tains the entire FACT G and additional items reﬂecting
HIV/AIDS speciﬁc concerns. This allows cross-disease
comparison of QOL through calculation of an HIV speciﬁc
score and a FACT G score derived from the FAHI. A SAS
(Cary, NC) program is available that calculates these
scores [13].
We used data from California Cancer Registry as of
April, 2008 to obtain information on chemotherapy, his-
tology, site and stage of NHL. We used the classiﬁcation
system of the International Classiﬁcation of Diseases for
Oncology (ICD-O Third Edition) [14] to divide the his-
tology into three categories: diffuse large B cell lymphoma
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123(DLBCL, code 9680 and 9684) follicular (codes 9690,
9691, 9695, and 9698) and other. We abstracted CD4 cell
counts and viral load results drawn within 3 months of
NHL diagnosis (but prior to chemotherapy) from the
medical record.
Statistical methods
We used SAS 9.2 for all statistical analyses. We performed
the chi-square test to compare proportions between cases
and controls. We used the t-test to compare mean QOL
scores between cases with or without a diagnosis of HIV
prior to NHL diagnosis and time between NHL diagnosis
and study entry between cases and controls. We used the
General Linear Model (GLM) procedure to compare
unadjusted quality of life scores between cases and con-
trols. Although we matched cases and controls on age, race
and sex, cases and controls differed socioeconomically and
biologically. To account for correlations among the QOL
subscales, we performed multivariate analysis of variance
(MANOVA) adjusting for all socioeconomic and biologic
variables that differed signiﬁcantly between cases and
controls (Table 1). We employed the Kaplan–Meier
method to calculate survival. All tests are two-sided with
p\.05 considered statistically signiﬁcant.
Results
Demographics
The sex distribution was 96% male (48 men and two
women in each matched group). There were 26 whites
(52%), 21 Latinos (42%), two African Americans (4%) and
one Asian (2%) in each group. The median age at NHL
diagnosis was 45 years (range 17–70). Controls were more
likely than cases to have private insurance (p\.03,
Table 1) and cases were more likely than controls to have
an annual income less than $20,000 (p\.001).
Clinical characteristics
HIV-infected individuals were more likely to have diffuse
large B cell lymphoma than controls and controls were
more likely to have follicular lymphoma than cases
(p\.001, Table 1). HIV-infected patients also were more
likely than uninfected patients to have extranodal lym-
phoma (p\.02). There was no statistical difference in
NHL stage (p\.59) or use of chemotherapy (p\.78)
between the two groups. Among the 50 cases, 24 (48%)
had prior AIDS (diagnosed either by opportunistic infec-
tion or CD4\200/mcl) and 15 (30%) did not have AIDS
Table 1 Characteristics of
Non-Hodgkin Lymphoma
(NHL) patients with and
without Human
Immunodeﬁciency Virus (HIV)
infection, residing in Orange
and San Diego Counties,
2002–2006
a One missing
HIV-NHL (N = 50)
N(column%)
NHL (N = 50)
N(column%)
p by v
2
Insurance .03
Government including Medicaid, Medicare,
county, veteran, military, and Ryan White
27 (54) 14 (28)
Private 14 (28) 21 (42)
Self pay/declined to state/do not know 9 (18) 15 (30)
Income .001
Less than $20,000 annual 23 (46) 9 (18)
$20,000 or more annual 18 (36) 37 (74)
Declined to state 9 (18) 4 (8)
Histology .001
Diffuse large B cell (including immunoblastic) 35 (70) 19 (38)
Follicular 0 (0) 17 (34)
Other 15 (30) 14 (28)
Nodal status .02
Nodal 34 (68) 44 (88)
Extranodal 16 (32) 6 (12)
Stage
a .59
Stage I–III 18 (37) 21 (42)
Stage IV 31 (63) 29 (58)
Chemotherapy .78
Yes 43 (86) 42 (84)
No 7 (14) 8 (16)
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123before NHL diagnosis; the AIDS history of the remaining
11 (22%) was unknown. Among 38 HIV-infected patients
with recorded laboratory values within 3 months of NHL
diagnosis yet prior to chemotherapy, the median CD4 cell
count was 157/mcl (range 15–750) and median HIV RNA
was 18,600 copies/ml (log 4.3) (range \50–880,000).
Although over half (54%) had a CD4 cell count\200/mcl,
more than one-third (34%) had an HIV RNA of \400
copies/ml.
Medical history survey
All subjects completed medical history and QOL surveys a
median 8 months after NHL diagnosis (range 0–16). Cases
completed the survey a median of 4 months after NHL
diagnosis (range 0–15) and controls completed the survey a
median of 11 months after NHL diagnosis (range 3–16)
(p\.001). Among 42 patients who recalled when they
were ﬁrst diagnosed with HIV infection, the median
duration of infection was 9 years (ranging from diagnosed
1 month after NHL diagnosis to 24 years prior to NHL
diagnosis). Among all 50 cases, 11 (22%) said they were
newly diagnosed with HIV. Twenty-eight (56%) reported
that they were taking HAART at the time of NHL diag-
nosis; 17 (34%) stated they were not taking HAART and
ﬁve (10%) did not know. By the time of survey completion,
39 (78%) were on HAART, seven (14%) were not and four
(8%) did not know.
Quality of life differences between NHL patients with
and without HIV Infection
NHL patients with HIV infection had worse overall QOL
than NHL patients without HIV infection (p\.0001,
Table 2). These differences were more marked (p\.005
by GLM) in the areas of functional, physical and social
well-being than in the area of emotional well-being. In the
MANOVA model adjusted for demographic and clinical
factors which were statistically signiﬁcantly different
between cases and controls (nodal status and histologic,
insurance and income categories shown in Table 1), emo-
tional well-being did not statistically differ between NHL
patients with and without HIV infection. NHL patients
without HIV infection had similar QOL scores to previ-
ously reported values for cancer patients [15].
Quality of life among HIV-infected NHL patients
versus reported HIV-infected patient norm
Table 3 shows QOL scores for HIV-infected patients as
measured by the FAHI. The overall QOL of current
patients with HIV-associated NHL is similar to that of
Table 2 Quality of life in patients with Non-Hodgkin Lymphoma
(NHL) with and without Human Immunodeﬁciency Virus Infection
(HIV) as measured by the Functional Assessment of Human
Immunodeﬁciency Virus Infection (FAHI) and Functional Assess-
ment of Cancer Therapy-General (FACT-G)
HIV-NHL (N = 50)
mean (SD)
NHL (N = 50)
mean (SD)
p by GLM
a comparing mean
in HIV-infected NHL versus
uninfected NHL
p by MANOVA
b comparing
mean in HIV-infected NHL
versus uninfected NHL
Reported cancer
patient norm
c
(N = 2,236)
Total 68.4 (15.9) 81.9 (16.1) .0001 .0001 80.9 (17.0)
Emotional well-being 17.3 (4.1) 18.9 (3.8) .05 0.19 18.7 (4.5)
Functional well-being 14.6 (6.2) 18.8 (7.0) .002 .0001 18.9 (6.8)
Physical well-being 18.0 (6.7) 22.3 (5.9) .001 .002 21.3 (6.0)
Social well-being 18.5 (6.5) 21.9 (5.1) .005 .03 22.1 (5.3)
a General linear model
b Multivariate analysis of variance model includes nodal status and histologic, insurance and income categories
c Normative data presented for comparison [15]
Table 3 Quality of life in
patients with Non-Hodgkin
Lymphoma (NHL) and Human
Immunodeﬁciency Virus
Infection (HIV) as measured by
the Functional Assessment of
HIV Infection quality of life
instrument (FAHI)
HIV and NHL
(N = 50) mean (SD)
Reported HIV-infected patient
norm [13]( N = 352) mean (SD)
Total mean (SD) 110.0 (26.5) 106.3 (26.0)
Emotional well-being mean (SD) 25.7 (9.3) 20.4 (8.6)
Functional well-being mean (SD) 29.6 (9.9) 32.2 (9.7)
Physical well-being mean (SD) 24.6 (10.0) 24.2 (9.5)
Social well-being mean (SD) 21.6 (7.3) 21.4 (6.7)
Cognitive functioning mean (SD) 8.5 (2.5) 8.1 (2.9)
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123historical HIV-infected patients without NHL [13]. The
emotional well-being score was higher for contemporary
HIV-infected patients with NHL than reported norms for
HIV-infected patients. The functional well-being score was
slightly lower for HIV-infected patients with NHL than
historical patients. Physical and social well-being and
cognitive functioning scores were similar to reported
norms. QOL scores (total and subscale) did not differ
between cases with prior HIV diagnoses and those who
were newly diagnosed (p[.05).
Survival
The median follow up time was 33 months (range 2–
66 months). Among the 50 cases, 17 died during follow-
up. Among the 50 controls, two died during follow-up.
Thus, survival among cases was worse than among controls
(p\.001). Because more than half of the subjects were
alive at most recent follow-up in both groups, it is
impossible to calculate a median survival (Fig. 1).
Discussion
Despite the availability of antiretrovirals and chemother-
apy, HIV-infected patients had worse overall QOL and
survival than uninfected patients with NHL. We anticipated
that we would ﬁnd a lower quality of life among the HIV-
infected NHL patients in all categories of well-being,
physical and functional as well as social and emotional.
However, we found that worse QOL among the HIV-
infected was due to lower functional, physical and social
well-being rather than emotional well-being (Table 2).
HIV-infected patients were more likely to have diffuse
large B cell and extranodal lymphoma (Table 1). These
biologic differences between NHL patients with and
without HIV infection combined with the debility and
medication management associated with concurrent HIV
infection may explain the lower physical QOL subscale
scores among the HIV-infected. HIV-infected patients had
less income and were less likely to have private insurance
than uninfected patients (Table 1), possibly contributing to
a lower functional QOL even prior to NHL diagnosis.
The low social well-being scores for the HIV-infected
may reﬂect lack of familial or partner support. HIV-
infected individuals may be estranged from their families
because of relatives’ concerns regarding risk factors for
HIV (e.g. homosexuality or injection drug use) or fear and
prejudice. Lack of partner support may be due to the death
or illness of an HIV-infected partner or lack of societal
support for same sex unions.
There was no statistical difference in emotional well-
being between cases and controls in the adjusted model.
The issues reﬂected in the emotional well-being score
(such as anxiety, hopelessness and fear of death) may be
equally concerning to both cases and controls. Alterna-
tively, some HIV-infected patients may have addressed
these issues in the past at the time of HIV diagnosis and
have become accustomed to living with them. We discuss
below how contemporary patients with HIV and NHL have
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123better emotional well-being subscale scores than historical
norms for HIV patients, suggesting that the availability of
HAART has inﬂuenced this subscale score in particular.
Although we initially hypothesized that contemporary
patients with HIV-infection and NHL would have worse
QOL than historical HIV-infected patients, we were sur-
prised to ﬁnd that the overall QOL of our patients with
HIV-associated NHL was similar to that of historical HIV-
infected patients without NHL as measured by the FAHI
(Table 3)[ 13]. These QOL norms for HIV-infected
patients are from the pre-HAART era and reﬂect the poor
prognosis and stigma associated with AIDS of that time.
Contemporary patients with HIV-associated NHL have
better emotional well-being than historical HIV-infected
patients, perhaps due to increased optimism about prog-
nosis due to the availability of HAART. The survival of
patients with HIV-associated NHL was better in our study
than historical ﬁgures [1], also reﬂecting the beneﬁt of
HAART.
While there was no difference between contemporary
and historical patients in the physical, social and cognitive
subscales, the functional well-being subscale score was
more than two points worse in contemporary HIV-infected
patients with NHL than among historical HIV-infected
patients but the difference was less than 0.5 standard
deviation (SD). In the interpretation of differences in
health-related quality of life, an effect size of 0.5 SD is a
relatively stable important difference [16]. The developers
of the FACT-G and FAHI consider a ﬁve point difference
in overall score and a two point difference in subscale score
as clinically meaningful for cancer patients [15]. A
decrease in functional well being could be due to the effect
of concurrent NHL and its treatment but might be mitigated
by antiretroviral therapy.
Beyond the beneﬁt of HAART, designing an interven-
tion to improve the QOL of patients with HIV and NHL is
not simple. Chemotherapy regimens of shorter duration
with fewer side effects and oral administration would
improve QOL. In-home support, both physical and social,
to bridge the period of decreased function would improve
QOL. While home health care for hygiene requires in-
person assistance, perhaps social support could be provided
by telephone. Given that AIDS-related NHL is relatively
uncommon (390 cases per 100,000 person-years among
people with AIDS in 1996–2002) [17], there would be few
people able to participate in support groups for this illness.
Interventions in physician ofﬁces, infusion centers or hos-
pitals during routine care would be convenient for patients.
Since most physicians and nurses lack the training and time
to intervene, social workers or psychologists might play a
role. Given that many patients with HIV-related NHL are
poor and publicly insured, it is unclear how to cover the
costs of any intervention.
This manuscript is unique in that it is the only study, to
our knowledge, to use information from the cancer registry
to identify and contact patients with a HIV-related malig-
nancy. There was a population-based case–control study of
NHL using rapid case ascertainment in the San Francisco
Bay Area between 1988 and 1995. In that study, all sub-
jects received a questionnaire inquiring about their HIV
status and men had the option to participate in a laboratory
portion of the study that included HIV serologic testing
[18]. The standardized and validated QOL instruments
employed in the study enhance the value of our ﬁndings
[10–13, 15].
Our study is limited by the moderate number of subjects.
The high morbidity and mortality associated with AIDS
and lymphoma as well as the social and economic issues
discussed above made it challenging to contact and follow-
up cases. We also had difﬁculty ﬁnding controls matched
by age and race/ethnicity. Because there is no routine
system for rapid case ascertainment and we were afraid of
patients dying prior to study participation, we did not
standardize the time to interview. Since medical records
were scattered between HIV specialist and oncologist
ofﬁces and various hospitals, our information regarding
prior AIDS diagnoses and current CD4 cell counts is
incomplete. Some patients declined to answer survey
questions regarding their income and insurance, also
resulting in incomplete data.
Since some potential subjects died prior to contact, there
is bias toward improved survival in our HIV-infected study
participants compared with all HIV-infected patients with
lymphoma. The HIV-infected patients who participated
were healthy enough to give consent and complete the
surveys and thus were not representative of all HIV-
infected patients with NHL. Another source of bias is the
different NHL histology between cases and controls.
However, given the inherent imbalance in histologic pat-
tern between the HIV-infected and uninfected, it was not
feasible to match on histology as well as age, sex, and race/
ethnicity. Although we used the population-based cancer
registry to recruit, we matched our controls to cases; the
controls are not representative of all patients with systemic
NHL who would typically be older and include more
women than our controls. HIV infection in the United
States is more common in men than women, so our study
included few women [7].
Quality of the life among patients with lymphoma is an
important yet understudied topic. We conclude that even
among the HIV-infected lymphoma patients most likely to
do well, QOL and survival lag behind that of uninfected
patients. However, emotional QOL has improved com-
pared to historical HIV-infected patient norms. Survival
among HIV-infected patients with lymphoma also is better
than in the past. Despite the widespread availability of
154 Qual Life Res (2010) 19:149–155
123HIV-testing, undiagnosed individuals present with
advanced disease [19]. Similarly, not all HIV-infected
patients access antiretroviral therapy. The low CD4 cell
counts and elevated viral loads of our patients suggest
uncontrolled HIV infection and issues regarding antiretro-
viral access, adherence, tolerance and/or resistance.
Therefore, NHL will continue to be a source of morbidity
and mortality among the HIV-infected. Our study provides
a foundation for future research.
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